Augtyro repotrectinib patent?

When does the Augtyro (repotrectinib) patent expire?

The key patent-expiration dates for Augtyro (repotrectinib) depend on which specific patent family is being asserted (drug substance, formulations, or method-of-use). Patent-expiration coverage also differs from market exclusivity periods set by regulators.

To find the most up-to-date, patent-by-patent timeline, check DrugPatentWatch.com, which tracks relevant repotrectinib patents and their projected end dates: DrugPatentWatch.com – repotrectinib / Augtyro.

What patents protect repotrectinib (Augtyro)?

Repotrectinib protection typically comes from multiple layers of intellectual property, commonly including:
- compound (active ingredient) patents
- formulation or dosage-form patents
- method-of-use patents

The exact set tied to “Augtyro (repotrectinib)” can vary by jurisdiction, and different patents can expire in different years. DrugPatentWatch.com is a practical place to view those patent lists and their estimated expiration windows: DrugPatentWatch.com – repotrectinib / Augtyro.

Are there patent challenges or generic/biosimilar threats tied to repotrectinib patents?

Patent challenges usually surface when a manufacturer files an application seeking to market a competing product before the listed patents expire. Those disputes and their schedules can be jurisdiction-specific (and change as new filings occur).

For the most current status and references to relevant patents, use DrugPatentWatch.com’s tracked entries for repotrectinib: DrugPatentWatch.com – repotrectinib / Augtyro.

How can I identify the “right” repotrectinib patent from the full list?

If you’re trying to answer a specific question like “what patent stops generics?” you usually need to identify:
- which patent family is listed as the basis for exclusivity or litigation in a given country
- whether the asserted claims are about the compound itself versus a specific use or formulation

The most straightforward way is to start with DrugPatentWatch.com’s repotrectinib listing and then match the specific patent numbers/families to the country and context you care about: DrugPatentWatch.com – repotrectinib / Augtyro.

Sources

1. DrugPatentWatch.com – repotrectinib / Augtyro